CD8A and neoplasm: This regimen, also known as “medium dose intermittent cyclophosphamide” (MEDIC), has been shown to have potent immunostimulatory effects on natural killer (NK) cells and also result in development of CD8+ T cell-mediated complete tumor regressions as well as generation of immune memory in a GL261 glioma model.